Host-directed therapeutics for tuberculosis: can we harness the host?
about
Tuberculosis vaccines and prevention of infectionVersatile myeloid cell subsets contribute to tuberculosis-associated inflammationProtection and pathology in TB: learning from the zebrafish modelCell death and autophagy in tuberculosisTuberculosis vaccines: barriers and prospects on the quest for a transformative toolDissection of the host-pathogen interaction in human tuberculosis using a bioengineered 3-dimensional modelLooking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosisNovel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosisNew tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeuticsMembrane Type 1 Matrix Metalloproteinase Regulates Monocyte Migration and Collagen Destruction in Tuberculosis.Permutations of time and place in tuberculosisThe Tyrosine Kinase Inhibitor Gefitinib Restricts Mycobacterium tuberculosis Growth through Increased Lysosomal Biogenesis and Modulation of Cytokine Signaling.Mycobacterium tuberculosis subverts negative regulatory pathways in human macrophages to drive immunopathology.Oral Administration of Heat-Killed Mycobacterium manresensis Delays Progression toward Active Tuberculosis in C3HeB/FeJ Mice.Cell-autonomous effector mechanisms against mycobacterium tuberculosis.Coincident helminth infection modulates systemic inflammation and immune activation in active pulmonary tuberculosis.Cytokine and lipid mediator networks in tuberculosisMycobacterium tuberculosis metabolismHost-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites.Targeting Batf2 for infectious diseases and cancer.Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary TuberculosisThe antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.Neutrophils: potential therapeutic targets in tularemia?The immune response and antibacterial therapy.Host-Directed Therapies for Tuberculosis.Newer patents in antimycobacterial therapy.The long and winding road to inhaled TB therapy: not only the bug's fault.The art of persistence-the secrets to Burkholderia chronic infections.Single cell biology beyond the era of antibodies: relevance, challenges, and promises in biomedical research.Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review.Antimycobacterial and Anti-inflammatory Mechanisms of Baicalin via Induced Autophagy in Macrophages Infected with Mycobacterium tuberculosis.Incidence and clinical profile of tuberculosis after allogeneic stem cell transplantation.Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.c-Abl-TWIST1 Epigenetically Dysregulate Inflammatory Responses during Mycobacterial Infection by Co-Regulating Bone Morphogenesis Protein and miR27a.A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis.The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy
P2860
Q26782022-FA7AD53F-1489-4854-A80B-8826BB25C956Q26997007-3C4E69DE-C6A3-4B30-BE77-F4AB6B06F634Q28266814-2004FDFF-4C7E-460F-ADF1-91DDC3F3AB38Q28387214-4F5E1B8E-6166-4AD4-A2B0-41BB715B9451Q28390218-4685DA5A-638D-4576-9C5F-2E0FC5190C6AQ28468572-7BFB12C3-1234-4AD9-A8EF-0604D8292385Q28538272-4975211D-BA16-4CF1-8D17-88CC096C0E40Q28830471-38F28394-A26F-4980-9709-923DF64C51CCQ30371980-058C2F98-C8E0-44BB-9379-0F902E02D9EEQ30375886-5A261835-3C3B-456C-A20B-A9344CB67CBFQ30378562-6A8E36BA-4B6B-4787-A11D-248BD30CDABCQ30402360-4F63F966-C0D2-43FA-9187-492B65BF1245Q30402626-2C517658-80C9-4A77-9B71-43E0739402AAQ31037455-EDC617DB-61DE-4566-85A7-130E8489CA0BQ34287676-AAFB6FF2-3AE3-4A52-B903-2A25EC5F90E2Q34465369-CB1D7F17-A65A-4E2A-B73D-5F7FD013FB14Q35117086-54C20352-C623-409C-96D2-101E9EB17A6AQ35245286-F5C77D54-54D4-4668-BADD-5ACE5FEB006CQ35594843-12442B96-A7B8-4605-A86B-05489782CE75Q36413539-4D719845-2FBF-44D8-9C7B-702DB6F53CE3Q36487876-636DC3CC-EF7A-4C7F-AE43-C1A968F98B6CQ37277346-42452EE6-670B-4C12-852B-F33EBB37773EQ37415488-555139A1-E6B2-4C14-A4AD-6542590640D0Q38246131-39DA2C5A-2976-44F6-AEC1-891CD25B3F6CQ38489473-CF8F2FA1-32C7-425B-AE9E-C6D66149EDEFQ38510495-4AB610D4-D3E9-47F9-B8E6-527A07741607Q38782463-64AF86BE-E6D0-419C-A71B-D96A1DE58A20Q38839466-A0FD9417-EF02-4371-95E1-3BEB61D24F00Q38974617-6F855DB4-FA4E-4289-A1B5-50104897A5CDQ39437994-DEA40878-C43C-48FC-9A8E-A6A205F3BC74Q47096875-8DFA19DE-1AE3-491C-9FC8-B0734B5A743BQ48138642-90586959-B300-46E8-A123-453543B28D32Q48355478-D8BCBE9D-B03A-4AB1-8872-AD5CB60D47EAQ49956938-E266AB1E-48CB-4BF8-9B67-BE9D16360AC3Q55378112-F922BF36-D265-4DCF-B588-2AAE0575012AQ58693717-9FB95157-CED8-4EF0-B963-EB1B7358917B
P2860
Host-directed therapeutics for tuberculosis: can we harness the host?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Host-directed therapeutics for tuberculosis: can we harness the host?
@en
type
label
Host-directed therapeutics for tuberculosis: can we harness the host?
@en
prefLabel
Host-directed therapeutics for tuberculosis: can we harness the host?
@en
P2093
P2860
P356
P1476
Host-directed therapeutics for tuberculosis: can we harness the host?
@en
P2093
Alastair I Matheson
Omar Vandal
Stephen N Maley
Thomas R Hawn
P2860
P304
P356
10.1128/MMBR.00032-13
P577
2013-12-01T00:00:00Z